Objective: To determine the factors a ecting the frequency and severity of oral mucositis are following hematopoietic stem cell transplantation. Study Design: Descriptive study. Place and Duration of the Study: Armed Forces Bone Marrow Transplant Centre Rawalpindi, from September 2020 to February 2022. Methodology: Patients who underwent allogenic stem cell transplantation were enrolled. Patients were analysed based on history and examination for oral mucositis (OM) as per the WHO mucositis scale, from the start of conditioning chemotherapy till discharge, total duration of mucositis and type of medication were noted. Its association with risk factors like age, gender, conditioning chemotherapy, methotrexate (MTX) for GVHD prophylaxis, and prior history of irradiation was determined. Results: Mean age of the 72 transplant recipients was 21.9 ± 14 years, with 48 males and 24 females. The common underlying diseases were beta-thalassemia major (30.6%, n=22), acute lymphoblastic leukaemia (n=15, 20.8%), aplastic anaemia (n=10, 13.9%), and multiple myeloma (n=8, 11.1%). The frequency of mucositis in those aged under 15 years was 79.3% (n=23) and in those older than 15 years was 74.4% (n=32). Frequency of mucositis was statistically signi cant in patients who receive myeloablative conditioning regimen (85% vs. 20%, p <0.01), and who had prophylactic. MTX (91% vs. 48%, p<0.01) and who had prior craniospinal (CSI) radiation (100 %vs. 70.2%, p=0.01). There was no statistical signi cance between stem cell dose (CD34/TNC) and mucositis. Severity of mucositis was signi cantly greater in Allogenicvs. auto HSCT (p=0.04). All the patients with mucositis required analgesics for pain management. Conclusion: Oral mucositis is a common but potentially debilitating complication of stem cell transplant, requiring opioid analgesia in a signi cant number of cases. Myeloablative conditioning, prophylactic MTX, and prior CSI are signi cantly associated with mucositis in transplant patients.